Since establishing Chinese Peptide Company in China in 2001 and founding CPC Scientific in the United States in 2005, Medtide Inc. has evolved from a peptide synthesis specialist into a comprehensive peptide and oligonucleotide CRDMO platform now serving over 1,000 customers worldwide. What began as operations in China and the United States has expanded into a global business network spanning more than 50 countries and regions, positioning Medtide Inc. as a world-leading integrated peptide and oligonucleotide CRDMO service provider.
|
2001 |
-Chinese Peptide Company (wholly-owned subsidiary of Medtide Inc.) was established in the PRC in August 2001. |
|
2004 |
-Our research center was named as the "Zhejiang Province High-Tech Development Center”by Science Technology Department of Zhejiang. |
|
2005 |
-CPC Scientific, Inc. (wholly-owned subsidiary of Medtide Inc.) was established in Delaware, the United States. |
|
2006 |
-We successfully passed NMPA GMP inspection. |
|
2009 |
-We obtained the ISO13485:2003 quality management system certification. -Our first generic product LEUPROLIDE ACETATE obtained regulatory approvals from NMPA. |
|
2011-2016 |
-We have successfully passed four consecutive FDA inspections, indicating our full compliance with FDA regulatory standards and guidance. |
|
2018 |
-We successfully passed the GMP inspection of EMA. -We were named as "2018 Zhejiang Provincial International Science and Technology Cooperation Base” by Science Technology Department of Zhejiang. |
|
2019 |
-We successfully passed the GMP inspection of Ministry of Food and Drug Safety of Korea (MFDS). |
|
2020 |
-Medtide Inc. was established. -We supported our client in obtaining a conditional marketing authorization for a first-in-class peptide drug from the EMA. |
|
2021 |
-We officially initiated oligonucleotide CDMO operation. |
|
2022 |
-We acquired a site to construct our production facility in Rocklin, California, to provide GMP production services for peptide APIs, and to establish a global supply chain to support our customers worldwide. |
|
2023 |
-We successfully passed NMPA registration inspection and GMP inspection. -We were recognized as a “specialized, refined, and innovative" small and medium-sized enterprise in Zhejiang Province |
|
2024 |
-We obtained the GMP certificate issued by the TGA. -We were approved to establish a national postdoctoral research site. -We successfully passed the fifth FDA on-site GMP inspection, indicating our continuous full compliance with FDA regulatory standards and guidance. -We were rated as a High-growth Company in the Biopharmaceutical Industry of Zhejiang Province. -We were also rated as a National-level Specialized, Excellent, Featured and Innovative “Little Giant” Company. |
| 2025 |
-We obtained ISO22716:2007(E) Cosmetic Certification.
-We obtained marketing approval for Goserelin Acetate APIs. |
